Plain-English translation of NCT06137378 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding pembrolizumab (an immunotherapy drug that helps your immune system fight cancer) to standard chemotherapy and radiation improves outcomes for people with advanced throat cancer. The goal is to help more patients keep their voice box instead of having it surgically removed. Researchers will compare this new approach to standard treatment alone.
Currently, many people with advanced laryngeal or hypopharyngeal cancer need surgery to remove their larynx, which means they lose their natural voice. This medication aims to improve how well standard treatment works, potentially allowing more patients to avoid this life-changing surgery and preserve their ability to speak naturally.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first receive one round of chemotherapy, then have imaging tests to see how your cancer responds. Based on the results, you'll either receive additional chemotherapy and radiation (without surgery), or have surgery followed by radiation—and you may also receive the immunotherapy medication for up to 12 months depending on which group you're randomly assigned to. You'll have regular doctor visits and scans throughout the treatment period and follow-up visits afterward to monitor your health and quality of life.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Germany